JP2008513529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513529A5 JP2008513529A5 JP2007532821A JP2007532821A JP2008513529A5 JP 2008513529 A5 JP2008513529 A5 JP 2008513529A5 JP 2007532821 A JP2007532821 A JP 2007532821A JP 2007532821 A JP2007532821 A JP 2007532821A JP 2008513529 A5 JP2008513529 A5 JP 2008513529A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- concentrate
- prevention
- polyol
- suppression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 239000012141 concentrate Substances 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- -1 2,4,6-triisopropylphenylsulfonyl Chemical group 0.000 claims 5
- 229920005862 polyol Polymers 0.000 claims 5
- 150000003077 polyols Chemical class 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- DOGXZGWWONUGJF-QMMMGPOBSA-N (2S)-2-[[amino-(hydroxyamino)methylidene]amino]-3-phenylpropanoic acid Chemical class ONC(=N)N[C@H](C(O)=O)CC1=CC=CC=C1 DOGXZGWWONUGJF-QMMMGPOBSA-N 0.000 claims 1
- MVTHUEOHHHQQKY-QMMMGPOBSA-N (2s)-2-(diaminomethylideneamino)-3-phenylpropanoic acid Chemical class NC(N)=N[C@H](C(O)=O)CC1=CC=CC=C1 MVTHUEOHHHQQKY-QMMMGPOBSA-N 0.000 claims 1
- KIPIDQBXOKPNDP-QMMMGPOBSA-N (2s)-2-[(diaminomethylideneamino)-hydroxyamino]-3-phenylpropanoic acid Chemical class NC(N)=NN(O)[C@H](C(O)=O)CC1=CC=CC=C1 KIPIDQBXOKPNDP-QMMMGPOBSA-N 0.000 claims 1
- MJIDYLIDXWGFRN-QMMMGPOBSA-N (2s)-2-[2-(diaminomethylidene)hydrazinyl]-3-phenylpropanoic acid Chemical class NC(=N)NN[C@H](C(O)=O)CC1=CC=CC=C1 MJIDYLIDXWGFRN-QMMMGPOBSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 201000002543 age related macular degeneration 2 Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007974 sodium acetate buffer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000005760 tumorsuppression Effects 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004045720A DE102004045720A1 (de) | 2004-09-21 | 2004-09-21 | Stabile Dosierungsform von Phenylalanin-Derivaten |
| DE102004045720.4 | 2004-09-21 | ||
| PCT/EP2005/010143 WO2006032461A1 (de) | 2004-09-21 | 2005-09-20 | Stabile dosierungsform von phenylalanin-derivaten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513529A JP2008513529A (ja) | 2008-05-01 |
| JP2008513529A5 true JP2008513529A5 (enExample) | 2008-08-14 |
| JP5054529B2 JP5054529B2 (ja) | 2012-10-24 |
Family
ID=35429536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532821A Expired - Fee Related JP5054529B2 (ja) | 2004-09-21 | 2005-09-20 | フェニルアラニン誘導体の安定な投与形 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9089532B2 (enExample) |
| EP (1) | EP1799265B1 (enExample) |
| JP (1) | JP5054529B2 (enExample) |
| KR (1) | KR101228385B1 (enExample) |
| CN (1) | CN1993144B (enExample) |
| AT (1) | ATE480260T1 (enExample) |
| AU (1) | AU2005287582B2 (enExample) |
| BR (1) | BRPI0515533B8 (enExample) |
| CA (1) | CA2580639C (enExample) |
| DE (2) | DE102004045720A1 (enExample) |
| ES (1) | ES2347670T3 (enExample) |
| MX (1) | MX2007000399A (enExample) |
| RU (1) | RU2358736C2 (enExample) |
| WO (1) | WO2006032461A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| CN115515560B (zh) | 2020-03-10 | 2023-12-15 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA986594B (en) * | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
| PT1264828E (pt) * | 1998-07-20 | 2004-08-31 | Wilex Ag | Inibidor de uroquinase |
| DE50209313D1 (de) * | 2001-12-12 | 2007-03-08 | Wilex Ag | Selektive arylguanidinpeptide als urokinaseinhibitoren |
| ATE399175T1 (de) * | 2002-03-11 | 2008-07-15 | Curacyte Ag | Hemmstoffe der urokinase, ihre herstellung und verwendung |
| DE10225876A1 (de) * | 2002-06-11 | 2003-12-24 | Wilex Ag | Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren |
| US7247724B2 (en) * | 2002-07-25 | 2007-07-24 | Wilex Ag | Method for the production of phenylalanine derivatives |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
-
2004
- 2004-09-21 DE DE102004045720A patent/DE102004045720A1/de not_active Withdrawn
-
2005
- 2005-09-20 WO PCT/EP2005/010143 patent/WO2006032461A1/de not_active Ceased
- 2005-09-20 CN CN2005800256252A patent/CN1993144B/zh not_active Expired - Fee Related
- 2005-09-20 BR BRPI0515533A patent/BRPI0515533B8/pt not_active IP Right Cessation
- 2005-09-20 KR KR1020077005447A patent/KR101228385B1/ko not_active Expired - Fee Related
- 2005-09-20 MX MX2007000399A patent/MX2007000399A/es active IP Right Grant
- 2005-09-20 US US11/631,891 patent/US9089532B2/en active Active
- 2005-09-20 RU RU2007115064/15A patent/RU2358736C2/ru active
- 2005-09-20 ES ES05786251T patent/ES2347670T3/es not_active Expired - Lifetime
- 2005-09-20 EP EP05786251A patent/EP1799265B1/de not_active Expired - Lifetime
- 2005-09-20 CA CA2580639A patent/CA2580639C/en not_active Expired - Fee Related
- 2005-09-20 AU AU2005287582A patent/AU2005287582B2/en not_active Ceased
- 2005-09-20 AT AT05786251T patent/ATE480260T1/de not_active IP Right Cessation
- 2005-09-20 DE DE502005010237T patent/DE502005010237D1/de not_active Expired - Lifetime
- 2005-09-20 JP JP2007532821A patent/JP5054529B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105534970B (zh) | 高浓度奥洛他定眼用组合物 | |
| CN100540006C (zh) | 铂衍生物药物制剂 | |
| US20040110828A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
| JP2013513612A5 (enExample) | ||
| TWI574692B (zh) | 偏亞砷酸鈉於治療白血病及淋巴瘤之用途 | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| ES2546672T3 (es) | Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona | |
| CN105963244A (zh) | 注射用青蒿琥酯制剂及其应用 | |
| JP7440630B2 (ja) | ウルソデオキシコール酸の注射用組成物 | |
| PT1224188E (pt) | Composição de administração nasal que compreende o sal metanossulfonato de morfina e quitosano | |
| EP1206256B1 (en) | Combination therapy using pentafluorobenzenesulfonamide and platin compound | |
| EP2621485A2 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| JP2008513529A5 (enExample) | ||
| JP6498610B2 (ja) | カバジタキセル組成物 | |
| CN101123957B (zh) | 双氯芬酸及其药学上可接受盐的注射剂 | |
| MX2008010394A (es) | Tratamientos antivirales intravenosos. | |
| CN114929213A (zh) | 碱性化疗药瘤内注射剂组合物 | |
| EP4076442A1 (en) | Pharmaceutical composition of cyclooxygenase - 2 inhibitors | |
| CN103462891B (zh) | 一种异硫氰酸烯丙酯胶束制剂 | |
| US20150057305A1 (en) | Pharmaceutical composition | |
| RU2007115064A (ru) | Стойкая лекарственная форма из производных фенилаланина | |
| JP2025522933A (ja) | メルファランを含む安定した液体医薬組成物 | |
| JPH10251151A (ja) | 癌転移阻害剤 | |
| JP2022505200A (ja) | 希釈安定性に優れたテニポシド注射用溶液及びその調製方法 |